Retatrutide 10mg

Retatrutide (LY3437943) is an experimental triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors — a previously unique combination in peptide research. In preclinical animal studies on obese mice and rats, retatrutide led to body-weight reductions of 20–30 % within 12 weeks, significantly stronger than semaglutide comparison groups.